George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and as such demonstrating product value in terms of clinical effectiveness, specialized cohorts and tolerability.


George Clinical is a leading provider of oncology trial, scientific, and operational solutions throughout the Asia-Pacific, USA and Europe.

As a leader in the design and delivery of care-based, oncology research, George Clinical has access to significant global investigator networks, experienced project teams, oncology experts, and scientific leaders to design and deliver oncology trials, with the latest immunotherapies, to the highest scientific standards. By accessing some of the world’s most experienced medical, scientific and operational teams in oncology research, George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and thus demonstrates product value in terms of clinical effectiveness, specialized cohorts and tolerability.

Exceptional medical, scientific and operational expertise makes George Clinical an ideal partner for clinical trials throughout North America, Europe and the Asia-Pacific.

Oncology Expertise

George Clinical has extensive experience in all phases of oncology programs including, MTD, early Phase I, II and III and late-phase trials, health economics and outcomes research. Our full services team is comprised of scientific leaders, doctors, nurses, biostatisticians and trial management professionals that work together to ensure timely delivery of quality trial data on time and on budget.

George Clinical offers a unique combination of scientific leadership and operational capabilities to design and deliver studies for sponsors, no matter the complexity. George Clinical offers:

  • Full service clinical operations and capabilities with experience in the conduct of over 300 oncology studies
  • A robust network of practicing medical oncologists with expertise across a range of tumor types, hematologic diseases and the latest immunotherapies, who actively participate in the design and delivery of our studies
  • World-class Health Economics and Statistics scientific leaders with expertise in large, multi-regional datasets

George Clinical’s extensive experience in oncology trials provides sponsors with the confidence that their oncology trial will be delivered on time, on budget and to the highest scientific standards.

Webinar: Managing Oncology Trials in the Era of COVID-19

Our clinical trial services in oncology clinical trials include:

George Clinical's Oncology Scientific Leadership

Dipti Talaulikar

  • Senior Consultant, Hematology, Canberra Hospital and Associate Professor, ANU

Associate Professor Dipti Talaulikar is a Senior Consultant in Clinical and Laboratory Hematology at Canberra Hospital and Associate Professor at the Australian National University (ANU). She is also a long-standing member of Myeloma Australia’s Medical and Scientific Advisor Group, as well as other leading cancer trial and research groups. She is dedicated to improving patient wellbeing and has authored both national and international clinical practice guidelines that have had a significant impact on cancer patient care. She has also served as Principal Investigator and co-investigator of several lymphoma, leukemia and myeloma trials.

Dr. Talaulikar contributes to medical workforce development and advocacy for equity of access to diagnostic tests and blood cancer treatments through leadership roles in organizations such as Royal College of Pathologists of Australasia (RCPA), National Blood Authority and Myeloma Australia. She is recognized as a key opinion leader (KOL) and is regularly invited to participate in Advisory Boards of pharmaceutical companies to provide guidance into clinical development of drugs, feedback into trial protocols and insights into research opportunities.

Primary research interests include breast cancer, supportive care and developmental therapeutics. Recently involved with genomic profiling of advanced cancer. Interested in visionary approaches to clinical research and oncology science. Divides his time between individual patients in the clinic and conducting clinical research trials and programmatic development.

Dr. Ari VanderWalde is an internationally recognized researcher providing expertise in oncology clinical trials with a focus on immune therapies in solid tumors and melanoma. He has worked in the pharmaceutical industry helping lead the approval of a new compound in Melanoma. Along with this experience, he also works at a premier cancer research institute and as a scientific expert in a global CRO specializing in oncology. 

In addition, Dr. VanderWalde has collaborated and participated on advisory boards with many of the nation’s thought leaders and top experts in the field and holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology. He is involved in research that can improve treatment for cancer patients by targeting therapy in a more personalized fashion based on immune markers and aberrations in cancer genetics.

Specializes in medical oncology, hematology and blood cancers. Interested in research and immunology. Committed to providing patients with access to early-stage clinical trials. In partnership with Methodist Healthcare, facilitated FDA approval for lifesaving CAR T therapy in 2019.

Board certified in both hematology and oncology. Has a research interest in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. Conducts research in exploring the latest advances colorectal cancer treatment. Offers individualized care to patients with focus on multi-modal treatment regimens.

Specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer. Advises patients on participating in clinical trials for leading-edge treatments. Emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options.

I wish to subscribe to George Clinical communications.

Add George Clinical to your network